Strides Pharma [STAR] vs Natco Pharma [NATCOPHARM] Detailed Stock Comparison
Strides Pharma
NSE
Loading...
Natco Pharma
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Strides Pharma wins in 8 metrics, Natco Pharma wins in 12 metrics, with 0 ties. Natco Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Strides Pharma | Natco Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 21.92 | 8.77 | Natco Pharma |
| Price-to-Book Ratio | 2.94 | 2.17 | Natco Pharma |
| Debt-to-Equity Ratio | 72.67 | 3.67 | Natco Pharma |
| PEG Ratio | 12.64 | 22.36 | Strides Pharma |
| EV/EBITDA | 11.48 | 6.51 | Natco Pharma |
| Profit Margin (TTM) | 7.38% | 42.57% | Natco Pharma |
| Operating Margin (TTM) | 15.11% | 36.84% | Natco Pharma |
| EBITDA Margin (TTM) | 15.11% | 36.84% | Natco Pharma |
| Return on Equity | 138.93% | 27.97% | Strides Pharma |
| Return on Assets (TTM) | 59.41% | 15.78% | Strides Pharma |
| Free Cash Flow (TTM) | $4.42B | $11.85B | Natco Pharma |
| Dividend Yield | 0.74% | 0.68% | Strides Pharma |
| 1-Year Return | -29.61% | -36.97% | Strides Pharma |
| Price-to-Sales Ratio (TTM) | 1.63 | 3.73 | Strides Pharma |
| Enterprise Value | $90.73B | $142.94B | Natco Pharma |
| EV/Revenue Ratio | 1.96 | 3.23 | Strides Pharma |
| Gross Profit Margin (TTM) | 60.32% | 79.59% | Natco Pharma |
| Revenue per Share (TTM) | $503 | $247 | Strides Pharma |
| Earnings per Share (Diluted) | $37.12 | $105.27 | Natco Pharma |
| Beta (Stock Volatility) | 0.57 | 0.19 | Natco Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Strides Pharma vs Natco Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Strides Pharma | 0.76% | -3.84% | -7.07% | 26.63% | 9.57% | 14.21% |
| Natco Pharma | -3.94% | -2.50% | -7.83% | 13.12% | -29.19% | -35.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Strides Pharma | -29.61% | 130.32% | 44.47% | -33.73% | 100.09% | 182.26% |
| Natco Pharma | -36.97% | 40.23% | 9.43% | 95.78% | 2,249.99% | 3,682.50% |
Performance & Financial Health Analysis: Strides Pharma vs Natco Pharma
| Metric | STAR | NATCOPHARM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹75.67B | ₹165.27B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 624,765 | 568,600 |
| 90 Day Avg. Volume | 495,285 | 1,431,394 |
| Last Close | ₹804.40 | ₹907.80 |
| 52 Week Range | ₹513.05 - ₹1,675.00 | ₹726.80 - ₹1,639.00 |
| % from 52W High | -51.98% | -44.61% |
| All-Time High | ₹1,675.00 (Oct 14, 2024) | ₹1,639.00 (Sep 09, 2024) |
| % from All-Time High | -51.98% | -44.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.14% |
| Quarterly Earnings Growth | 0.42% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.07% | 0.43% |
| Operating Margin (TTM) | 0.15% | 0.37% |
| Return on Equity (TTM) | 1.39% | 0.28% |
| Debt to Equity (MRQ) | 72.67 | 3.67 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹276.88 | ₹424.69 |
| Cash per Share (MRQ) | ₹21.55 | ₹162.87 |
| Operating Cash Flow (TTM) | ₹36.02B | ₹16.97B |
| Levered Free Cash Flow (TTM) | ₹35.93B | ₹8.90B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.74% | 0.68% |
| Last 12-Month Dividend | ₹6.50 | ₹6.00 |
Valuation & Enterprise Metrics Analysis: Strides Pharma vs Natco Pharma
| Metric | STAR | NATCOPHARM |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 21.92 | 8.77 |
| Forward P/E | 12.64 | 22.36 |
| PEG Ratio | 12.64 | 22.36 |
| Price to Sales (TTM) | 1.63 | 3.73 |
| Price to Book (MRQ) | 2.94 | 2.17 |
| Market Capitalization | ||
| Market Capitalization | ₹75.67B | ₹165.27B |
| Enterprise Value | ₹90.73B | ₹142.94B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.96 | 3.23 |
| Enterprise to EBITDA | 11.48 | 6.51 |
| Risk & Other Metrics | ||
| Beta | 0.57 | 0.19 |
| Book Value per Share (MRQ) | ₹276.88 | ₹424.69 |
Financial Statements Comparison: Strides Pharma vs Natco Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | STAR | NATCOPHARM |
|---|---|---|
| Revenue/Sales | ₹11.20B | ₹12.21B |
| Cost of Goods Sold | ₹4.44B | ₹2.49B |
| Gross Profit | ₹6.75B | ₹9.72B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.69B | ₹4.50B |
| EBITDA | ₹2.27B | ₹6.14B |
| Pre-Tax Income | ₹1.22B | ₹5.06B |
| Income Tax | ₹164.50M | ₹999.00M |
| Net Income (Profit) | ₹1.06B | ₹4.06B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | STAR | NATCOPHARM |
|---|---|---|
| Cash & Equivalents | ₹1.13B | ₹1.20B |
| Total Current Assets | ₹31.02B | ₹52.70B |
| Total Current Liabilities | ₹25.92B | ₹9.44B |
| Long-Term Debt | ₹6.23B | ₹46.00M |
| Total Shareholders Equity | ₹25.86B | ₹76.12B |
| Retained Earnings | ₹4.59B | N/A |
| Property, Plant & Equipment | ₹8.81B | ₹24.32B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | STAR | NATCOPHARM |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | STAR | NATCOPHARM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 624,765 | 568,600 |
| Average Daily Volume (90 Day) | 495,285 | 1,431,394 |
| Shares Outstanding | 92.16M | 179.11M |
| Float Shares | 56.69M | 81.34M |
| % Held by Insiders | 0.33% | 0.51% |
| % Held by Institutions | 0.25% | 0.13% |
Dividend Analysis & Yield Comparison: Strides Pharma vs Natco Pharma
| Metric | STAR | NATCOPHARM |
|---|---|---|
| Last 12-Month Dividend | ₹6.50 | ₹6.00 |
| Last 12-Month Dividend Yield | 0.74% | 0.68% |
| 3-Year Avg Annual Dividend | ₹2.67 | ₹7.00 |
| 3-Year Avg Dividend Yield | 0.32% | 0.28% |
| 3-Year Total Dividends | ₹8.00 | ₹21.00 |
| Ex-Dividend Date | Jul 22, 2025 | Feb 18, 2025 |